Published in Drug Week, May 13th, 2005
The United States District Court for the Southern District of New York entered into a consent dismissal ending the pending litigation between the 2 companies. These arrangements have been established to provide benefits to millions of female patients who have multiple lipid disorders and are candidates for Kos' niacin-based pharmaceutical cholesterol products.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.